Comparing two very low cholesterol targets for high-risk heart patients
Part of Heart & circulation clinical trials.
This trial compares two very low LDL-cholesterol targets (below 1.0 vs 1.0-1.39 mmol/L) using extra medications (PCSK9 inhibitors) to see which is safer and better for people at extremely high risk of heart attacks or strokes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have very high risk of heart disease or stroke (as defined by the study), such as having had two or more major events like heart attack or stroke in the past two years, or one event plus additional risk factors.
- Your LDL ('bad') cholesterol is at least 1.0 mmol/L even after taking maximum-tolerated statin and ezetimibe for at least 4 weeks.
- You are able to attend follow-up visits and have no severe liver or kidney problems.
- You are not allergic or intolerant to statins, ezetimibe, or PCSK9 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
This study tests whether an educational program can help people with high cholesterol and heart disease get their LDL cholesterol levels lower. It involves watching online videos and working with your doctor to adjust treatments.
This trial compares different LDL cholesterol targets to find the best level for people at very high risk after a heart stent procedure. It tests whether aiming for a lower cholesterol goal improves outcomes.
This trial tests whether higher doses of cholesterol-lowering medication (statins) can slow down plaque buildup in the heart arteries of younger and middle-aged adults with stable chest pain. It may help prevent heart attacks and the need for procedures like stents.
This study tests an experimental drug (QLC7401) that may help lower LDL ('bad') cholesterol in people who already have high cholesterol or mixed hyperlipidemia. If you're on stable cholesterol medication but still need more lowering, this trial could offer another option.
Hear when a new Atherosclerotic Cardiovascular Disease (ASCVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.